



Welcome
to those who bring
brightness back

**BRIGHT
EYES™** **HIT™**
Holistic Individualized Treatment
by GALDERMA

Brighten your patients outlook! Target tear
trough deformity (TTD) and smooth wrinkles
in the periorbital area using an individualized
selection of Galderma products.
For results as unique as you.

Restylane Botulinum Toxin
GALDERMA
EST. 1981



Welcome
to the new generation
of individualized aesthetics

Start from your patients insights to turn your AART™ into a HIT™

A same patient concern may have different causes. Therefore, it requires different solutions. It requires a Holistic Individualized Treatment. A HIT™.

A PATIENT-CENTRIC APPROACH

A new patient-centric approach building on the AART™ of GAIN to assess and treat patients individually:

A - Assessment

Start from your patients' concerns and assess their needs accurately with the Galderma Facial Assessment Scale

A - Anatomy

Understand how patients' anatomy contributes to the symptoms

R - Range

Prioritize the right selection of Galderma products

T - Treatment

Deliver individualized results patients desire


A SCIENCE-BASED SOLUTION

The Galderma Facial Assessment Scale (FAS), a more structured facial assessment to help guide aesthetic consultations.

Galderma FAS is made of five facets to ensure that all aspects of the patient's face are evaluated during the consultation.

- SKIN QUALITY
- FACIAL SHAPE
- FACIAL PROPORTION & CONTOUR
- FACIAL SYMMETRY
- ANIMATION & EMOTIONAL EXPRESSION

Those five facets can be graded according to their level of severity **to identify treatment priorities that can also be visualized by the patient.**



Unlock the potential of Galderma products offering to increase patient satisfaction.¹⁻³

72%

of patients who received an explanation, covering both physiological and anatomical perspectives, went on to schedule a treatment and increased their satisfaction.⁴

The eyes area, a major patient concern

5 out of 6 highest concerns are in the upper face regardless of age⁵

#1 is **dark circles** under or around the eyes⁵

70% of all people surveyed feel **they look tired and older** due to under-eye shadows⁵

2 out of 3 **are open to treat tear troughs⁵**.
The willingness to address this issue is strong.



BRIGHT EYES™

HIT™

Holistic Individualized Treatment
by GALDERMA

A HIT for the periorbital area for a brighter look

with Restylane® fillers and/or Alluzience®
& Azzalure® neuromodulators

Complementary usage of neuromodulators and dermal fillers offers an excellent approach to minimally invasive rejuvenation of the periocular area.⁶

The use of dermal fillers in combination with neuromodulators has the added benefit of approximately doubling the half-life of the filler.⁷

Alluzience® is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.⁵

⁶ Azzalure® is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown and/or lateral canthal lines (crow's feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.⁷

BRIGHT EYES™: 3 CORE PROFILES ENCAPSULATING PATIENTS NEEDS

FROM TIRED LOOK

FROM GRUMPY LOOK




FROM AGING

EXPRESSION OF PATIENT'S CONCERN

"It is a defect that I've always had and that I'd like not to have."

"People ask me if I am feeling OK all the time..."

"When looking in the mirror, my tired eyes do not correspond to me feeling good."



OBSERVATION

Mild to severe periorbital hollows

Mild to severe periorbital hollows
Presence of crow's feet and glabellar lines

Mild to severe periorbital hollows
Presence of crow's feet and glabellar lines
Lack of volume in the midface and temples

AART™ METHODOLOGY : ASSESSMENT, ANATOMY, RANGE, TREATMENT

- TT indication¹⁰

Restylane
EYELIGHT

- TT indication¹⁰

Restylane
EYELIGHT

+

- Botulinum Toxin

- TT indication¹⁰

Restylane
EYELIGHT

+

- Temple and midface^{14,15}

Restylane
VOLUME

+

- Botulinum Toxin

TO LUMINOUS LOOK

TO RELAXED LOOK

TO YOUTHFUL LOOK

From tired look to luminous look

EXPRESSION OF PATIENT'S CONCERN

"It is a defect that I've always had and that I'd like not to have."

OBSERVATION

Mild to severe periorbital hollow


A ASSESSMENT

SEVERITY EVALUATION SCALES

STATIC LINES & TEAR TROUGH EVALUATION



DYNAMIC LINES




A ANATOMY


Normal condition



Mild to severe periorbital hollows



TTD due to atrophy of the skin and the subcutaneous fat in the suborbital area



Prominent nasojugal groove and subcutaneous fat in the suborbital area

R RANGE

Restylane® EYELIGHT™ is a NASHA technology injectable dermal filler, safe and trusted that reduces the grooves caused by lack of volume in the under-eye area to visibly reduce signs of fatigue.^{10,16}



88.6% of patients felt they looked less tired after treatment with Restylane® EYELIGHT™.¹⁰

T TREATMENT


Individualize the treatment plan to your patients needs to deliver the best possible outcome and increase patient satisfaction.

Adapt the treatment to your style, using either a cannula or needle.¹⁰
All treatment session could be performed using only 0.5mL regardless of age and/or gender.¹⁰

INJECTION SITES

- TT indication¹⁰

Restylane
EYELIGHT



From grumpy look to relaxed look

EXPRESSION OF PATIENT'S CONCERN

" People ask me if I am feeling OK all the time..."

OBSERVATION

Mild to severe periorbital hollows
 Presence of crow's feet and glabellar lines


A ASSESSMENT

SEVERITY EVALUATION SCALES

STATIC LINES & TEAR TROUGH EVALUATION



DYNAMIC LINES




A ANATOMY

Normal condition



Mild to severe periorbital hollows
Presence of crow's feet and glabellar lines



TTD due to contraction of the orbicularis oculi muscle or squinting

R RANGE

Restylane® EYELIGHT™ is a targeted under-eye treatment with predictable results.^{10,17} Restylane® gives precise projection to the periorbital hollow and reduces shadows for a noticeably refreshed appearance.^{10,18}

82.9% saw a noticeable **improvement** in the appearance of dark shadows.¹⁰



Botulinum Toxin

T TREATMENT

Individualize the treatment plan to your patients needs to deliver the best possible outcome and increase patient satisfaction.

Adapt the treatment to your style with Restylane®, using either a cannula or needle.¹⁰

All Restylane® EYELIGHT™ treatment session could be performed using only 0.5mL regardless of age and/or gender.¹⁰

INJECTION SITES

- TT indication¹⁰
- Botulinum Toxin

Restylane
EYELIGHT

Images of the packaging may vary – for illustration purposes only.

*Alluzience® is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.⁸

**Azzalure® is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown and/or lateral canthal lines (crow's feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.⁹

From aging to youthful look

EXPRESSION OF PATIENT'S CONCERN



"When looking in the mirror, my tired eyes do not correspond to me feeling good."

OBSERVATION

- Mild to severe periorbital hollows
- Presence of crow's feet and glabellar lines
- Lack of volume in the midface and temples

A ASSESSMENT

SEVERITY EVALUATION SCALES



In order to properly adapt treatment strategies to individual patients' needs, consider the specific anatomical deformities observed in the periorbital region of the patient being assessed and the relationships these structures have with nearby areas of the midface (e.g., malar area, zygomatic arch).

A ANATOMY


Normal condition



Mild to severe periorbital hollows / Presence of crow's feet and glabellar lines / Lack of volume in the midface and temples



TTD caused by herniated orbital fat



Infraorbital hollowness due to malar bone resorption and soft tissue atrophy

R RANGE

Restylane® EYELIGHT™ will replenish lost volume, lifts, and smooths the under-eye area.¹⁰

Subjects reported appearing **an average of M: -3.14 years (SD: 3.12) younger** after treatment.²⁰

Restylane® VOLYME™ is an OBT™ (Optimal Balance Technology) that will correct midface and temple volume loss by restoring natural-looking volume and create fullness.^{15,21,22}

98% were still pleased with the durability of their results at 18 months.¹⁵



Botulinum Toxin


T TREATMENT

Individualize the treatment plan to your patients needs to deliver the best possible outcome and increase patient satisfaction.

Adapt the treatment to your style with Restylane®, using either a cannula or needle.¹⁰

High performance for optimal results:

- All treatment session could be performed using only one 0.5mL syringe of Restylane® EYELIGHT™.¹⁰
- With Restylane® VOLYME™, optimal aesthetic results can be achieved with 13% less volume (4.3 mL) compared to Juvéderm VOLUMA (4.9 mL).²⁴



INJECTION SITES

- TT indication¹⁰



- Temple & midface^{14,15}



- Botulinum Toxin

Images of the packaging may vary – for illustration purposes only.

*Alluzience® is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.⁸

**Azzalure® is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown and/or lateral canthal lines (crow's feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.⁹

GALDERMA,
ADVANCING DERMATOLOGY
FOR EVERY SKIN STORY

With a unique legacy in dermatology and decades of cutting-edge innovation, we deliver a science-based portfolio of premium flagship brands and services that spans the full spectrum of dermatology.

Everyone's skin is unique, and we all have our own skin story. We embrace these differences to meet the individual needs of the consumers, patients and customers we serve.

This would not have been possible without you, and we are committed to accompany you on your journey. We want to help you shape the future of aesthetics, in order to improve patient satisfaction and create more smiles.



LET'S SHAPE NEW AESTHETIC POSSIBILITIES TOGETHER


Join our community on GAIN Connect,
Galderma Aesthetic Healthcare Practitioner Portal, to:

- Find expert product information and assets
- Access industry-leading education and training
- Discover tools to help you run and grow your business

JOIN GAIN
GAIN ▶
GALDERMA AESTHETIC INJECTOR NETWORK



SEE THE AFTER BEFORE



Be a leader for the future of the beauty industry.

Experience FACE by Galderma™ the cutting-edge aesthetic visualization app that uses interactive augmented reality to help your patients see injectable treatment results in real-time.

3 out of 4

patients using FACE by Galderma™
sought more treatments than they
previously considered.²⁵

REFERENCES

- Cartier, Hugues et al. "Repeated Full-Face Aesthetic Combination Treatment With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin-Boosting Hyaluronic Acid After Monotherapy With AbobotulinumtoxinA or Hyaluronic Acid Filler." *Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al.]* vol. 46,4 (2020): 475-482.
- Hedén, Per et al. "Effective and Safe Repeated Full-Face Treatments With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin Boosting Hyaluronic Acid." *Journal of drugs in dermatology : JDD* vol. 18,7 (2019): 682-689.
- Molina, Beatriz et al. "Patient Satisfaction and Efficacy of Full-Facial Rejuvenation Using a Combination of Botulinum Toxin Type A and Hyaluronic Acid Filler." *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]* vol. 41 Suppl 1 (2015): S325-32.
- Freedman, B M et al. "Employing a teaching module improves patient satisfaction in facial rejuvenation." *Journal of cosmetic dermatology* vol. 5,2 (2006): 127-9.
- Data on file (MA-46075). "Restylane Eyelight Opticom European Market Survey Results." Result report. November 2020.
- Lee WW, Levitt AE. "Periocular rejuvenation with neurotoxin and dermal filler." *Plast Aesthet Res* 2018;5:43.
- Coleman, Kiersten R, and Jean Carruthers. "Combination therapy with BOTOX and fillers: the new rejuvenation paradigm." *Dermatologic therapy* vol. 19,3 (2006): 177-88.
- Galderma Alluzience® SmPC. August 2022: 1-10.14.
- Galderma Azzalure® SmPC. August 2022: 1-9.
- Nikolis, Andreas et al. "A Randomized, Crossover-Controlled Evaluator-Blinded Trial Evaluating Cannula vs Needle-Assisted Hyaluronic Acid Injections for Infraorbital Deformities." *Aesthetic surgery journal* vol. 42,3 (2022): 285-297.
- Ascher, Benjamin et al. "Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial." *Aesthetic Surgery Journal* vol. 40,9 (2020): 1000-1008.
- Kestemont, Philippe et al. "Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study." *Aesthetic surgery journal* vol. 42,3 (2022): 301-313.
- Ascher, Benjamin et al. "Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study." *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]* vol. 35,10 (2009): 1478-1486.
- Restylane Volyme. Instructions for Use, Galderma. March 2020.
- Talarico, Sergio et al. "High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study." *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]* vol. 41,12 (2015): 1361-9.
- Nikolis, Andreas et al. "Expert Recommendations on the Use of Hyaluronic Acid Filler for Tear Trough Rejuvenation." *Journal of drugs in dermatology : JDD* vol. 21,4 (2022): 387-392.
- Verpaele, Alexis, and Anders Strand. "Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face." *Aesthetic surgery journal* vol. 26,1S (2006): S10-7.
- Data on file (MA-33947). "Product integration comparison of different hyaluronan based fillers after injection in human ex vivo skin." 2017.
- Punga, Anna Rostedt et al. "A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines." *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]* vol. 42,8 (2016): 967-76.
- Data on file (MA-48305). "Data on File infraorbital deformities submitted manuscript. Appraisal of clinical investigational data on the Restylane Eyelight submitted to Aesthetic Surgery Journal." 2021.
- Nikolis, Andreas et al. "The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness?" *Aesthetic surgery journal. Open forum* vol. 2,1 ojaa005. 6 Feb. 2020.
- Kestemont, Philippe et al. "Sustained efficacy and high patient satisfaction after cheek enhancement with a new hyaluronic acid dermal filler." *Journal of drugs in dermatology : JDD* vol. 11,1 Suppl (2012): s9-16.
- Schlessinger, J. et al. "A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines." *Dermatol Surg* 47, 504-509 (2021).
- Jones, Derek et al. "A Randomized, Comparator-Controlled Study of HARC for Cheek Augmentation and Correction of Midface Contour Deficiencies." *Journal of drugs in dermatology : JDD* vol. 20,9 (2021): 949-956.
- Face App Pilot Results. Pilot conducted from November 2020 to 27 of September 2021. Results are coming from online survey done by 239 patients from 12 countries after being exposed to the Face App.

Restylane, Alluzience, Azzalure and Galderma are registered trademarks.

GALDERMA

EST. 1981

www.galderma.com



משווק בלעדית ע"י אמי טכנולוגיות חפשו אותנו ב: [in](https://www.linkedin.com) [@](https://www.instagram.com) [f](https://www.facebook.com) | [09-7760300](tel:09-7760300) | ami.co.il | amiweb@ami.co.il